| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 1.74B | 1.66B | 1.36B | 966.22M | 817.08M |
| Gross Profit | 202.39M | 176.85M | 161.50M | 134.78M | 63.66M | 82.58M |
| EBITDA | 41.97M | 24.25M | 27.18M | -14.55M | -214.97M | 27.22M |
| Net Income | 18.17M | 14.38M | 23.08M | -8.59M | -188.23M | 31.24M |
Balance Sheet | ||||||
| Total Assets | 1.35B | 1.14B | 999.90M | 792.81M | 686.37M | 328.97M |
| Cash, Cash Equivalents and Short-Term Investments | 441.35M | 491.15M | 389.51M | 347.99M | 320.58M | 84.63M |
| Total Debt | 6.24M | 5.59M | 8.29M | 11.50M | 46.50M | 33.66M |
| Total Liabilities | 588.23M | 452.34M | 392.51M | 273.76M | 236.19M | 185.32M |
| Stockholders Equity | 709.12M | 635.18M | 561.44M | 499.09M | 426.87M | 146.75M |
Cash Flow | ||||||
| Free Cash Flow | 109.50M | 104.26M | 80.67M | 47.09M | 54.51M | 38.51M |
| Operating Cash Flow | 110.70M | 109.28M | 80.78M | 47.20M | 55.06M | 38.89M |
| Investing Cash Flow | -96.52M | -10.32M | -48.01M | -104.00K | -32.77M | -380.00K |
| Financing Cash Flow | 5.18M | 2.68M | 8.74M | -19.68M | 213.66M | -767.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $2.98B | 163.03 | 2.74% | ― | 19.01% | 38.68% | |
69 Neutral | $674.95M | 32.68 | 5.87% | 0.52% | 3.68% | 5.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $362.63M | -1.53 | -47.69% | ― | -5.30% | 46.01% | |
48 Neutral | $463.14M | -2.65 | -13.63% | ― | -16.65% | -71.92% | |
47 Neutral | $1.34B | -5.95 | -15.42% | ― | -2.37% | 77.85% |
Privia Health Group, Inc. announced the acquisition of an Accountable Care Organization business from Evolent Health, Inc. The transaction, which was initially announced on September 23, 2025, was finalized on December 5, 2025, potentially enhancing Privia’s market positioning and operational capabilities.
The most recent analyst rating on (PRVA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.
On October 24, 2025, Patricia Maryland, a member of the Board of Directors and Chair of the Compliance Committee at Privia Health Group, passed away. The company expressed sadness at her passing and gratitude for her significant contributions over the past five years.
The most recent analyst rating on (PRVA) stock is a Buy with a $24.50 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.